Versatile functions for IL-6 in metabolism and cancer

Trends in Immunology

Volumn 36, Issue 2, 2015, Pages 92-101

  Mauer, Jan ^a   Denson, Jesse L ^a   Brüning, Jens C ^a  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Cancer; Inflammation; Interleukin 6; Metabolism

Indexed keywords

INTERLEUKIN 6;

EXERCISE; HUMAN; LIVER METABOLISM; MACROPHAGE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MUSCLE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TIGHT JUNCTION;

EID: 84963952313     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2014.12.008     Document Type: Review

References (125)

1. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115:1111-1119.
2. Mantovani A., et al. Cancer-related inflammation. Nature 2008, 454:436-444.
3. Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. 2008, 181:151-160.
4. Ellingsgaard H., et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 2011, 17:1481-1489.
5. White P.J., et al. Protectin DX alleviates insulin resistance by activating a myokine-liver glucoregulatory axis. Nat. Med. 2014, 20:664-669.
6. Grivennikov S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
7. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
8. Park E.J., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
9. Mauer J., et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol. 2014, 15:423-430.
10. Gruber S., et al. Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6Ra signaling. Cell Rep. 2013, 4:669-680.
11. Ouchi N., et al. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11:85-97.
12. Arkan M.C., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 2005, 11:191-198.
13. Cai D., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11:183-190.
14. Kleinridders A., et al. MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab. 2009, 10:249-259.
15. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
16. Wernstedt Asterholm I., et al. Adipocyte inflammation is essential for healthy adipose tissue expansion and remodeling. Cell Metab. 2014, 20:103-118.
17. Hotamisligil G.S., et al. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
18. Yuan M., et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
19. Zhang D., et al. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J. Biol. Chem. 1996, 271:9503-9509.
20. Visser M., et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131-2135.
21. Bastard J.P., et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 2000, 85:3338-3342.
22. Pradhan A.D., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
23. Bastard J-P., et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J. Clin. Endocrinol. Metab. 2002, 87:2084-2089.
24. Kim H-J., et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004, 53:1060-1067.
25. Klover P.J., et al. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005, 146:3417-3427.
26. Carey A.L., et al. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 2004, 47:1029-1037.
27. Carey A.L., et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006, 55:2688-2697.
28. Wallenius V., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 2002, 8:75-79.
29. Wallenius K., et al. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem. Biophys. Res. Commun. 2002, 293:560-565.
30. Li G., et al. Induction of uncoupling protein 1 by central interleukin-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats. Neuroscience 2002, 115:879-889.
31. Di Gregorio G.B., et al. Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E182-E187.
32. Matthews V.B., et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010, 53:2431-2441.
33. März P., et al. Sympathetic neurons can produce and respond to interleukin 6. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:3251-3256.
34. Jansson J-O., et al. On the site and mechanism of action of the anti-obesity effects of interleukin-6. Growth Horm. IGF Res. 2003, 13:S28-S32.
35. Hodes G.E., et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:16136-16141.
36. Gauldie J., et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:7251-7255.
37. Ramadoss P., et al. STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Mol. Endocrinol. 2009, 23:827-837.
38. Inoue H., et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 2004, 10:168-174.
39. König M., et al. Quantifying the contribution of the liver to glucose homeostasis: a detailed kinetic model of human hepatic glucose metabolism. PLoS Comput. Biol. 2012, 8:e1002577.
40. Ferrannini E. The target of metformin in type 2 diabetes. N. Engl. J. Med. 2014, 371:1547-1548.
41. Inoue H., et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006, 3:267-275.
42. Brüning J.C., et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000, 289:2122-2125.
43. McGuinness O.P., et al. NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E849-E855.
44. Könner A.C., et al. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab. 2007, 5:438-449.
45. Wunderlich F.T., et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 2010, 12:237-249.
46. Awazawa M., et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011, 13:401-412.
47. Sabio G., et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008, 322:1539-1543.
48. Gibbs J.E., et al. The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:582-587.
49. Bosenberg A.T., et al. Strenuous exercise causes systemic endotoxemia. J. Appl. Physiol. 1988, 65:106-108.
50. Drenth J.P., et al. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. J. Appl. Physiol. 1995, 79:1497-1503.
51. Steensberg A., et al. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J. Physiol. 2000, 529:237-242.
52. Pedersen B.K., Fischer C.P. Beneficial health effects of exercise - the role of IL-6 as a myokine. Trends Pharmacol. Sci. 2007, 28:152-156.
53. Kelly M., et al. Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes 2009, 58:1953-1960.
54. Serrano A.L., et al. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008, 7:33-44.
55. Ellingsgaard H., et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:13163-13168.
56. Wellen K.E., Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 2003, 112:1785-1788.
57. Xu H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
58. Lumeng C.N., et al. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007, 117:175-184.
59. Krawczyk C.M., et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010, 115:4742-4749.
60. Biswas S.K., Mantovani A. Orchestration of metabolism by macrophages. Cell Metab. 2012, 15:432-437.
61. Patsouris D., et al. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008, 8:301-309.
62. Odegaard J.I., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
63. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
64. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
65. Duluc D., et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007, 110:4319-4330.
66. Murray P.J., et al. Perspective. Immunity 2014, 41:14-20.
67. Lumeng C.N., et al. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008, 57:3239-3246.
68. Lang R., et al. Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 2002, 169:2253-2263.
69. Herbert D.R., et al. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 2004, 20:623-635.
70. Vats D., et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab. 2006, 4:13-24.
71. Wu D., et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011, 332:243-247.
72. Wermeling F., et al. Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:13487-13491.
73. Garbers C., et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012, 23:85-97.
74. Komori T., et al. Lack of oncostatin M receptor leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype. J. Biol. Chem. 2013, 288:21861-21875.
75. Komori T., et al. Deficiency of oncostatin receptor β (OSMRβ) exacerbates high-fat diet-induced obesity and related metabolic disorders in mice. J. Biol. Chem. 2014, 289:13821-13837.
76. Fritz D.K., et al. Oncostatin M (OSM) primes IL-13- and IL-4-induced eotaxin responses in fibroblasts: regulation of the type-II IL-4 receptor chains IL-4Ralpha and IL-13Ralpha1. Exp. Cell Res. 2009, 315:3486-3499.
77. Hutchins A.P., et al. Genome-wide analysis of STAT3 binding in vivo predicts effectors of the anti-inflammatory response in macrophages. Blood 2012, 119:e110-e119.
78. Nishimura S., et al. Adipose natural regulatory B cells negatively control adipose tissue inflammation. Cell Metab. 2013, Published online October 22, 2014. http://dx.doi.org/10.1016/j.cmet.2013.09.017.
79. Kemna E. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005, 106:1864-1866.
80. Nguyen K.D., et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 2011, 480:104-108.
81. Stanford K.I., et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J. Clin. Invest. 2013, 123:215-223.
82. Wu J., et al. Adaptive thermogenesis in adipocytes: is beige the new brown?. Genes Dev. 2013, 27:234-250.
83. Petruzzelli M., et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 2014, 20:433-437.
84. Cressman D.E., et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996, 274:1379-1383.
85. Naugler W.E., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
86. Gao S.P., et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 2007, 117:3846-3856.
87. Sansone P., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117:3988-4002.
88. Rebouissou S., et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009, 457:200-204.
89. Reynaud D., et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011, 20:661-673.
90. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004, 4:579-591.
91. Wunderlich F.T., et al. Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proceedings of the National Academy of Sciences 2008, 105:1297-1302.
92. Fisher D.T., et al. The two faces of IL-6 in the tumor microenvironment. Semin. Immunol. 2014, 26:38-47.
93. Gilbert L.A., Hemann M.T. Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes Dev. 2012, 26:1758-1768.
94. Okada M., et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J. Exp. Med. 1983, 157:583-590.
95. Kishimoto T. The biology of interleukin-6. Blood 1989, 74:1-10.
96. Coulie P.G., et al. High-affinity binding sites for human 26-kDa protein (interleukin 6, B cell stimulatory factor-2, human hybridoma plasmacytoma growth factor, interferon-beta 2), different from those of type I interferon (alpha, beta), on lymphoblastoid cells. Eur. J. Immunol. 1987, 17:1435-1440.
97. Hirano T., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986, 324:73-76.
98. Zilberstein A., et al. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J. 1986, 5:2529-2537.
99. May L.T., et al. Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:8957-8961.
100. Haegeman G., et al. Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur. J. Biochem. 1986, 159:625-632.
101. Yamasaki K., et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988, 241:825-828.
102. Taga T., et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989, 58:573-581.
103. Akira S., et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994, 77:63-71.
104. Starr R., et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997, 387:917-921.
105. Ahmed S.T., Ivashkiv L.B. Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J. Immunol. 2000, 165:5227-5237.
106. Ehlting C., et al. Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by TNF-alpha involves activation of the MKK6/p38MAPK/MK2 cascade. J. Immunol. 2007, 178:2813-2826.
107. Zhang H., et al. STAT3 restrains RANK- and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13. Nat. Commun. 2014, 5:1-10.
108. Dittrich A., et al. Glucocorticoids increase interleukin-6-dependent gene induction by interfering with the expression of the suppressor of cytokine signaling 3 feedback inhibitor. Hepatology 2012, 55:256-266.
109. Wang R., et al. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem. 2005, 280:11528-11534.
110. Takahashi-Tezuka M., et al. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol. Cell. Biol. 1998, 18:4109-4117.
111. Lai C.F., et al. The STAT3-independent signaling pathway by glycoprotein 130 in hepatic cells. J. Biol. Chem. 1999, 274:7793-7802.
112. Matthews V., et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 2003, 278:38829-38839.
113. Chalaris A., et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007, 110:1748-1755.
114. Horiuchi S., et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur. J. Immunol. 1994, 24:1945-1948.
115. Yasukawa K., et al. Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J. Biochem. 1990, 108:673-676.
116. Lust J.A., et al. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992, 4:96-100.
117. Atreya R., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat. Med. 2000, 6:583-588.
118. Hurst S.M., et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001, 14:705-714.
119. Nowell M.A., et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 2003, 171:3202-3209.
120. Becker C., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
121. Narazaki M., et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993, 82:1120-1126.
122. Jones S.A., et al. IL-6 trans-signaling: the in vivo consequences. J. Interferon Cytokine Res. 2005, 25:241-253.
123. Scheller J., et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 2011, 1813:878-888.
124. Dittrich E., et al. A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J. Biol. Chem. 1996, 271:5487-5494.
125. Wunderlich C.M., et al. Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity. JAKSTAT 2013, 2:e23878.